Artren

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artren

Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Form Tablet, Capsule, Topical Gel, Solution, Suppository
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Provides analgesic and anti-inflammatory relief
Origin Synthetic, Phenylacetic acid derivative

What Type of Medicine is Artren?

Artren is a medicinal product whose active component is Diclofenac, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This categorization highlights its role in actively reducing the source of discomfort. It is a synthetic compound that belongs to the phenylacetic acid derivative chemical class. This identity is clinically recognized for its efficacy in blocking the inflammatory cascade. Artren exerts its effects as a Cyclooxygenase Inhibitor, which is the fundamental mechanism enabling its therapeutic actions.


Composition, Forms, and General Purpose

The medication is a single-component product (monotherapy), ensuring the focus is entirely on the action of Diclofenac, typically supplied as the sodium or potassium salt forms. Artren is distinguished by the breadth of its potential dosage forms, which include oral forms like tablets and capsules (including delayed or extended release), as well as targeted forms like topical gel, solution, and suppositories. The general purpose of Artren is to provide symptomatic relief from discomfort, fever, and stiffness. By intervening in the chemical processes that signal inflammation, the drug delivers reliable analgesic (pain-relieving) and anti-inflammatory benefits across affected body systems.

What side effects are possible with Artren?

Possible Side Effects and Safety Information

The official safety profile for Artren, which contains Diclofenac, organizes adverse reactions by the body systems affected and their documented frequency of occurrence. This organization is consistent across major governmental regulatory documents.

System-Organ Classes and Frequency

Adverse reactions classified as common in official labels (occurring in up to 1 in 10 patients) often involve the Gastrointestinal System, including symptoms such as nausea, diarrhea, indigestion, abdominal pain, flatulence, headache, and dizziness. Rare effects (up to 1 in 1,000) include more serious conditions like gastrointestinal bleeding or ulceration, asthma, and hepatic dysfunction. Very rare events (up to 1 in 10,000) include severe skin reactions and serious cardiovascular issues.

Serious Adverse Reactions and Risk Patterns

The regulatory labeling prominently highlights risks for serious adverse reactions, which can occur with or without warning symptoms. These include potentially fatal cardiovascular thrombotic events, such as myocardial infarction and stroke, where risk may increase with the duration and dose of use. Similarly, serious gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines, are documented risks.

Safety Considerations for Specific Populations

Safety statements in the regulatory text specify certain limitations. The medicine is officially contraindicated in the setting of coronary artery bypass graft (CABG) surgery and during the third trimester of pregnancy. Older adults are officially noted as being at a greater risk for serious gastrointestinal adverse events. For long-term treatment, official labels recommend the monitoring of blood count and hepatic function as precautionary safety measures.

Overdose and Emergency Response

Overdose with Artren, which contains Diclofenac, is officially documented to present with a range of symptoms and may lead to severe systemic outcomes. Early clinical manifestations commonly listed in regulatory documents include lethargy, drowsiness, nausea, vomiting, and epigastric pain. Signs of gastrointestinal bleeding are also a documented concern following exposure to amounts greater than the recommended dose. A large overdose is officially noted to be potentially very harmful to both children and adults.

Due to the potential for severe toxicity, regulatory guidance mandates that patients or caregivers seek immediate medical attention or contact emergency services right away if an overdose is suspected. Severe manifestations, though sometimes rare, are officially documented to include acute renal failure, respiratory depression, seizures, and coma. These life-threatening outcomes underscore the urgency required when managing overdose situations.

Regarding management, official prescribing information confirms that no specific antidote is known or available for acute Diclofenac toxicity. Treatment is restricted to symptomatic and supportive measures, with monitoring of vital signs and laboratory function being essential. In cases of large ingestions, procedures like administering activated charcoal may be considered as supportive measures to manage the toxicity.

Therapeutic Uses of Artren

Artren is used for easing symptoms that interfere with daily functioning and are related to inflammatory or irritative states.

Easing Pain and Reducing Symptoms of Inflammation

Artren is applied in contexts where additional symptomatic support is needed for discomfort, relevant for managing symptoms associated with acute or episodic changes. This medicine is commonly used to help with symptoms in conditions involving episodic or fluctuating manifestations, applicable within clinical settings that involve acute or disruptive symptom patterns. It helps address symptom clusters that may become intense or disruptive, especially those symptoms related to inflammatory or irritative states, providing support that contributes to easing the overall symptom load.

Improving Comfort and Functional Stability

The medication is considered relevant for easing symptoms that create noticeable functional strain, such as stiffness and tenderness in joints. It is often used during phases when symptoms become more noticeable, offering supportive relief that may help patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Joint Stiffness Symptoms The medication is considered relevant for easing symptoms that create noticeable functional strain, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Diclofenac

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Artren — Official Regulatory Information

Artren is a Nonsteroidal Anti-inflammatory Drug (NSAID) whose use is strictly governed by population eligibility rules from official regulatory sources. The medicine is broadly allowed for most adults for approved indications, and for certain oral forms in children twelve years and older, but use is often restricted below this age.


Absolute Contraindications (Must Not Use)

Category Regulatory Status
Prior Hypersensitivity Prohibited for patients with an allergy to Artren or a history of NSAID-induced asthma or allergic reactions [Source 1.4].
Cardiovascular Status Contraindicated in established heart conditions, including Ischaemic Heart Disease, Cerebrovascular Disease, Peripheral Arterial Disease, and Congestive Heart Failure (NYHA Class II-IV) (Systemic forms) [Source 2.6].
Gastrointestinal Status Contraindicated in patients with active GI ulceration, bleeding, or perforation [Source 2.1].
Surgical Setting Contraindicated for the management of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery [Source 1.4].
Pregnancy Absolutely Contraindicated in the third trimester (at or after 30 weeks gestation) [Source 1.4].

Restricted or Conditional Use

Eligibility is limited or requires mandatory close monitoring for: Older adults (due to increased risk of GI/renal events), patients with significant cardiovascular risk factors (e.g., hypertension, diabetes), and those with a history of GI bleeding or ulcer disease [Source 1.3, 2.6]. Use is generally not recommended while breastfeeding, although limited data suggest low transfer into milk [Source 4.3]. The medicine is contraindicated in severe renal and severe hepatic failure [Source 1.5, 2.1].

What should I know about interactions with other medicines?

Artren, which contains the active substance Diclofenac, has formally documented interaction patterns that are classified according to their potential to alter drug concentrations and increase additive risks. Certain combinations are officially categorized as prohibited or requiring significant constraints.

Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) should be avoided due to the documented potential for additive adverse effects. The use of Artren is also contraindicated for treating perioperative pain following Coronary Artery Bypass Graft (CABG) surgery.

The medicine can be subject to pharmacokinetic changes. For example, the presence of certain CYP enzyme inhibitors (like Voriconazole) results in a documented increase in the plasma levels (Cmax and AUC) of Diclofenac. Conversely, Diclofenac itself decreases the elimination of other substances, including Lithium and Methotrexate, leading to increased exposure of those drugs.

Pharmacodynamic interactions involve heightened risks. Combining Artren with Anticoagulants (e.g., Warfarin) or SSRIs (Selective Serotonin Reuptake Inhibitors) results in an officially recognized increased risk of bleeding. When combined with ACE Inhibitors or Diuretics, the risk of deterioration of renal function is documented. Concomitant use of Alcohol also increases the risk of serious gastrointestinal bleeding. For certain oral formulations, administration must be on an empty stomach as directed in the product labeling. Interaction risks are officially noted to be higher in elderly patients and those who are volume-depleted.

Mechanism of Action

Artren: Mechanism of Action

Artren (Diclofenac) operates within the eicosanoid pathway modulation domain by exerting a non-selective, competitive inhibitory effect on the Cyclooxygenase (COX-1 and COX-2) enzymes. This binding interaction prevents the COX isoforms from catalyzing the conversion of their substrate, arachidonic acid, into prostanoids, including prostaglandins. This molecular interruption is the primary step in the mechanistic cascade.

Limiting the synthesis of these mediators reduces the chemical signals that drive local vascular changes and sensitize peripheral nociceptors. The suppression of the inducible COX-2 enzyme primarily affects acute prostanoid synthesis, leading to the modulation of peripheral nociceptor signaling and reduced localized tissue permeability. Simultaneously, the drug's influence on constitutive COX-1 activity modulates essential physiological housekeeping functions, which is inherent to its overall pharmacodynamic profile.

Dosage and Administration Information

How Artren is Used: Official Administration Guidelines

Artren (Diclofenac) is administered following established clinical guidelines. All usage decisions must follow the principle of employing the lowest effective dose for the shortest duration possible.


Approved Routes and Forms

Artren is available in multiple forms to support different routes of administration, including:

  • Systemic: Oral (tablets, capsules, solutions), Intramuscular (IM) Injection, and Intravenous (IV) Infusion or Bolus.
  • Local: Topical/Cutaneous (gels, solutions) and Rectal (suppositories).

Standard Dosing and Frequency

Standard adult oral dosing typically ranges from 25 mg to 75 mg per dose, taken up to three or four times daily, depending on the specific formulation. The maximum recommended daily dose usually does not exceed 150 mg for many oral systemic forms. Parenteral (IM/IV) administration is often restricted to a maximum of two days of use, after which treatment must transition to oral or rectal forms.


Administration Requirements

Instruction Type Official Requirement
With/Without Food Certain forms (e.g., oral solution powder) must be taken on an empty stomach.
Preparation Oral solution powder must be mixed with 1 to 2 ounces of water only and consumed immediately. IV solutions require dilution and buffering.
Tablets Extended-release and delayed-release forms must be swallowed whole; they must not be crushed, broken, or chewed.

Population-Specific Use

Regulatory guidance emphasizes using the lowest effective dosage for older adults (geriatric patients) with particular caution. While dose adjustments for mild-to-moderate renal or hepatic impairment are not uniformly specified, caution is consistently advised for these patient populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Artren

Evidence for use in Chronic Joint Conditions

This section summarizes the types of high-level evidence, such as Randomized Controlled Trials (RCTs) and Systematic Reviews, that have evaluated the research base related to symptoms of chronic conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). It outlines what specific patient-reported outcomes, like pain and functional scores, were monitored in these studies.

Research exploring chronic conditions, primarily focusing on Osteoarthritis (OA), a condition marked by functional limitations and joint discomfort, has been conducted. Studies typically include short- to intermediate-term RCTs, where adults and older adults with OA are monitored over a period of weeks to a few months. These trials are relevant in evidence describing how symptoms are measured, focusing on patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level, such as standardized pain scales and function indices like WOMAC.

Findings describe patterns observed in the studies. Studies report on changes in patient-reported outcomes describing perceived discomfort. However, the evidence remains limited regarding the sustainability of these findings. Because follow-up durations were limited in most of the core efficacy trials, there is limited information for long-term outcomes, and certainty remains low regarding sustained effects beyond the trial period.

Evidence Summary for Osteoarthritis Symptoms

Short-term RCTs and subsequent meta-analyses of these trials are the main source of evidence for OA symptoms. These studies monitored adult and older adult populations with OA, often focusing on symptoms in the knee or hand. Findings describe patterns observed in the studies and report on the way patients reported their experience with physical discomfort. The current research provides context but not individual predictions regarding the maintenance of functional status over many months or years. Long-term effects are not fully established.

Evidence Summary for Rheumatoid Arthritis Symptoms

Studies observed Artren in the context of Rheumatoid Arthritis (RA), a condition involving periods of heightened symptoms. Research explored short-term symptom changes, sometimes including comparator treatments. Studies focused on measuring outcomes related to systemic or functional imbalance, specifically looking at things like joint tenderness and disease activity indices. Data show patterns related to how symptoms were tracked in the observed populations during the study period. Subgroup findings are uncertain, and data for certain groups within the RA population remain insufficient.

Evidence for use in Acute Pain and Injury

For acute pain and injury, the evidence is largely derived from short-term RCTs where studies observed responses over defined time intervals, often lasting a few days or weeks. This research examined conditions associated with acute or disruptive episodes, sometimes including conditions like sprains, strains, or localized soft tissue pain. Outcomes monitored included measurements of the rate of reported pain change and the proportion of patients capturing phases of heightened symptom activity who experienced a pre-defined level of change.

Long-Term Studies and Durability of Effect

The primary efficacy trials for chronic conditions like OA are generally short-term. Evidence exploring long-term use usually comes from observational settings evaluating daily-life functioning or pooled data from large programs, and these studies monitored physiological strain or stress over extended periods. Consequently, there is limited information for long-term outcomes on pain and functional measures beyond the initial short-term assessments.

Evidence in Specific Patient Groups

Older adults were included in many RCTs, particularly for OA, and research examined patient-reported outcomes describing perceived discomfort and daily functioning in this population. However, data for certain groups remain insufficient. For instance, evidence is limited or not consistently available for evaluation in pregnancy-related populations, children, or in patients with complex, co-existing, or unstable symptoms.

Key Limitations and Areas of Uncertainty in the Evidence

A primary limitation is that follow-up durations were limited in most efficacy studies, especially for chronic conditions where long-term use is common. As a result, there is limited information for long-term outcomes. Furthermore, comparative evidence is lacking in some scenarios, and evidence quality varies across studies when comparing different formulations or doses. Data for certain groups remain insufficient, meaning results apply only to the populations studied. Evidence describes what is known—and what is still uncertain—particularly concerning the safety profile during continuous, extended use.

Key Studies & References

  1. Diclofenac Topical (arthritis pain): MedlinePlus Drug Information (Authoritative summary of indications, dosing differences, and overall patient guidance)
  2. Diclofenac - StatPearls - NCBI Bookshelf (General medical review supporting use in acute pain, RA, and OA context)

Frequently Asked Questions (FAQ)

Common questions about Artren (FAQ)

Q: How quickly do people typically start feeling the effects of Artren?

A: Studies on the active ingredient indicate that the concentration in the bloodstream often peaks within two to three hours after taking an oral dose. For many forms, initial symptomatic improvement may begin to be noticed within about 30 minutes, though this can vary. Taking the medicine with food may slow down the speed at which it reaches its peak concentration.


Q: Are the side effects of Artren generally temporary or long-lasting?

A: Many of the common side effects, such as mild stomach discomfort or dizziness, may lessen as the body adjusts to the medicine. However, official safety information highlights that serious adverse events, like cardiovascular or severe gastrointestinal issues, are documented risks that can occur at any time, potentially having long-lasting or permanent consequences.


Q: Are there certain foods or supplements that should be avoided while taking Artren?

A: Regulatory guidance focuses primarily on documented drug-to-drug interactions. While there are no specific warnings against common foods, general medical resources advise disclosing all products, including supplements that may affect bleeding or fluid retention, as their interactions have not been consistently studied with the medicine.


Q: What happens if I stop taking Artren suddenly?

A: The medicine is not associated with dependency, meaning sudden stopping won't cause classical withdrawal symptoms. However, for certain conditions, abruptly discontinuing it may result in the return or worsening of the original symptoms, known as a rebound effect. Changes to the medicine regimen are typically managed under the supervision of a healthcare professional.


Q: Is it necessary to have routine blood tests while taking Artren?

A: Yes, official regulatory documents state that for patients receiving long-term treatment with the medicine, the regular monitoring of blood counts and hepatic (liver) function is often recommended. Such monitoring is described as a precautionary safety measure to track certain physiological effects during long-term use.


Q: What is the expected timeline for Artren to reach its full effect?

A: Clinical trials for chronic conditions such as osteoarthritis typically assess changes in symptoms over periods ranging from a few weeks to a few months. Official data suggests that the time to reach maximum benefit can differ significantly among patients, and it may not be immediate.


Q: What is the intended duration of action for a single dose of Artren?

A: The active substance in the medicine has a short half-life in the bloodstream, usually around 1.5 to 2 hours. Based on this, a single dose is generally expected to provide relief from symptoms for approximately four to eight hours.


Q: If Artren is stopped, do the original symptoms usually return?

A: The medicine provides symptomatic relief only; it does not cure the underlying condition. Because of this, once the medicine is discontinued, its anti-inflammatory and pain-relieving effects will cease, and the original symptoms for which it was taken are generally expected to return.


Q: Can Artren be used for conditions other than what it is mainly approved for?

A: The medicine is formally approved by regulatory agencies only for specific, documented uses, such as certain types of chronic joint conditions and acute pain. Any use outside of the formally approved indications is not mentioned in the product labeling.


Q: What is the difference between Artren and other similar medications I've seen?

A: Artren belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class and works by inhibiting COX enzymes. While many similar medicines share this mechanism, they may differ in their specific chemical structure, the body systems they affect most, or their available dosage forms, such as tablet versus topical gel.


Q: Is it common to feel tired when first starting Artren?

A: While tiredness, sleepiness, or lack of energy are not usually listed among the most frequent common adverse effects, official product safety data includes these effects. Patients should be aware that these effects have been reported in post-marketing surveillance or clinical studies.


Q: If I miss a dose of Artren, what should I generally do?

A: Official patient information often describes a general approach for a missed dose, typically advising against taking a double dose. Specific instructions for missed doses are found in the official patient information leaflet and should be consulted.


Q: What are the signs of a severe allergic reaction to Artren?

A: Signs of a severe allergic reaction, which is a rare event, can include difficulty breathing, wheezing, or swelling of the face, tongue, or throat. A serious, raised, itchy, or blistering rash is also noted in regulatory information. These documented symptoms are often noted to require prompt medical evaluation.


Q: Can Artren be taken with common vitamins or minerals?

A: Regulatory documents primarily focus on interactions with other prescription drugs. Since most common vitamins and minerals are not systematically tested for interactions with this medicine, general medical guidance suggests that patients typically disclose all supplements and vitamins when discussing their treatment plan.


Q: Does Artren have to be taken at a specific time of day?

A: The total daily amount of medicine is typically divided into two or three doses. Official information notes that to best address specific symptoms, such as morning stiffness or night discomfort, a dose may be suggested to be taken at bedtime, complementing any daytime doses.


Q: Is there a generic version of Artren available?

A: Yes, the active ingredient in Artren, which is Diclofenac, is available from numerous manufacturers. This means that generic equivalents of the medicine, which contain the same active ingredient, strength, and dosage form, are commonly available.


Q: Does Artren show up on standard drug tests?

A: The medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not designated as a narcotic or controlled substance. For this reason, standard drug screening panels, which typically look for controlled substances, do not screen for this type of medication.


Q: Is it safe to drive or operate machinery while using Artren?

A: Official labeling advises caution because the medicine can potentially cause side effects such as dizziness, sleepiness, or visual disturbances. If the medicine affects mental alertness, activities such as driving or operating heavy machinery may need to be postponed.


Q: What information should I have ready when discussing Artren with a healthcare professional?

A: Official guidance emphasizes discussing any existing cardiovascular conditions, a history of stomach bleeding or ulcers, and all current medications, especially blood thinners and other NSAIDs. Disclosing pregnancy status is also critical, as these areas are highlighted in the regulatory warnings for this drug class.


Q: Do official documents mention specific lifestyle changes while using Artren?

A: Yes, regulatory documents explicitly advise against the use of alcohol due to a documented increased risk of serious gastrointestinal bleeding. Additionally, for certain forms, such as topical gels, official information may mention sun sensitivity, suggesting sun avoidance.


Q: Can Artren cause changes in mood or sleep patterns?

A: Official labels list central nervous system (CNS) and psychiatric adverse reactions. These may include dizziness, anxiety, or depression. Sleepiness or drowsiness is also noted as a possible side effect in some product information.

How should Artren be stored and disposed of?

How to Store and Dispose of Artren? (Official Regulatory Information)

Official regulatory documents define mandatory requirements for the storage, protection, and disposal of Artren to maintain product quality.

Required Storage Conditions

Requirement Official Standard
Temperature Store below 25 C (Controlled Room Temperature).
Protection Protect from light and moisture; keep the product dry.
Handling Do not freeze. Keep the product in its original packaging.
Child Safety Keep Artren out of the reach and sight of children.

Stability and Disposal

The medicine has a defined shelf-life as indicated on the packaging. If Artren is reconstituted or opened, a specific in-use stability period applies, after which the product must be discarded. Disposal of unused or expired Artren must be performed via an official drug take-back program or according to regulatory guidelines for household trash; it must not be flushed down the toilet or poured down a drain unless specifically authorized by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artren found in:

A-Z Index: